Full text is available at the source.
Use of sodium–glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes
Use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes patients based on 2019 European and American treatment guidelines
AI simplified
Abstract
Approximately 80% of patients with type 2 diabetes were recommended treatment with SGLT2 inhibitors or GLP-1 receptor agonists according to the 2019 ESC guidelines.
- 79.5% of patients were recommended any of the two drugs based on the 2019 ESC guidelines.
- 48.8% of patients were recommended any of the two drugs based on the 2019 ADA/EASD consensus report.
- SGLT2 inhibitors were recommended for 37.2% of patients under both guidelines.
- GLP-1 receptor agonists were recommended for 1.4% according to the ESC guidelines and 11.6% according to the ADA/EASD report.
- Only 33.7% of those recommended treatment according to the ESC guidelines actually received it.
- 25.4% of patients recommended treatment according to the ADA/EASD consensus report received the treatment.
AI simplified